Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer.

Trial Profile

Phase II Multicenter Study Evaluating the Tolerability and Efficacy of RAD001 (Everolimus) in Patients With Relapsed or Metastatic Endometrial Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2014

At a glance

  • Drugs Everolimus (Primary)
  • Indications Endometrial cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENDORAD
  • Most Recent Events

    • 02 Jul 2012 This trial is recruiting in France.
    • 12 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top